Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Mar 25

PMID 27011176

Citations 26

Authors

Lei Dang

Jin Liu

Fangfei Li

Luyao Wang

Defang Li

Baosheng Guo

Xiaojuan He

Feng Jiang

Chao Liang

Biao Liu

Shaikh Atik Badshah

Bing He

Jun Lu

Cheng Lu

Aiping Lu

Ge Zhang

Affiliations

Soon will be listed here.

Abstract

Abnormalities in the integral components of bone, including bone matrix, bone mineral and bone cells, give rise to complex disturbances of skeletal development, growth and homeostasis. Non-specific drug delivery using high-dose systemic administration may decrease therapeutic efficacy of drugs and increase the risk of toxic effects in non-skeletal tissues, which remain clinical challenges in the treatment of skeletal disorders. Thus, targeted delivery systems are urgently needed to achieve higher drug delivery efficiency, improve therapeutic efficacy in the targeted cells/tissues, and minimize toxicities in non-targeted cells/tissues. In this review, we summarize recent progress in the application of different targeting moieties and nanoparticles for targeted drug delivery in skeletal disorders, and also discuss the advantages, challenges and perspectives in their clinical translation.

Citing Articles

Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus.

Sato T, Chaugule S, Greenblatt M, Gao G, Shim J Hum Gene Ther. 2024; 35(9-10):329-341.

PMID: 38661537 PMC: 11238950. DOI: 10.1089/hum.2024.034.

Engineering small-molecule and protein drugs for targeting bone tumors.

Wang Y, Wang C, Xia M, Tian Z, Zhou J, Berger J Mol Ther. 2024; 32(5):1219-1237.

PMID: 38449313 PMC: 11081876. DOI: 10.1016/j.ymthe.2024.03.001.

Surface-Modified Silica Hydrogels for the Programmable Release of Bisphosphonate Anti-Osteoporosis Drugs: The Case of Etidronate.

Alatzoglou F, Vassaki M, Nirgianaki K, Tripodianos E, Turhanen P, Demadis K Materials (Basel). 2023; 16(9).

PMID: 37176259 PMC: 10180253. DOI: 10.3390/ma16093379.

miRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling.

Wang S, Maruyama E, Martinez J, Lopes J, Hsu T, Wu W Elife. 2023; 12.

PMID: 36752600 PMC: 9946445. DOI: 10.7554/eLife.79768.

Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress.

Sui B, Liu J, Zheng C, Dang L, Chen J, Cao Y Int J Oral Sci. 2022; 14(1):39.

PMID: 35915088 PMC: 9343357. DOI: 10.1038/s41368-022-00193-1.

References

Ferreira D, Boratto F, Nascimento Cardoso V, Serakides R, Fernandes S, Ferreira L . Alendronate-coated long-circulating liposomes containing 99mtechnetium-ceftizoxime used to identify osteomyelitis. Int J Nanomedicine. 2015; 10:2441-50. PMC: 4381632. DOI: 10.2147/IJN.S76168. View

Mukherjee S, Ray S, Thakur R . Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2010; 71(4):349-58. PMC: 2865805. DOI: 10.4103/0250-474X.57282. View

Combes C, Rey C . Amorphous calcium phosphates: synthesis, properties and uses in biomaterials. Acta Biomater. 2010; 6(9):3362-78. DOI: 10.1016/j.actbio.2010.02.017. View

Orriss I, Key M, Colston K, Arnett T . Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem. 2008; 106(1):109-18. DOI: 10.1002/jcb.21983. View

Feng X, McDonald J . Disorders of bone remodeling. Annu Rev Pathol. 2010; 6:121-45. PMC: 3571087. DOI: 10.1146/annurev-pathol-011110-130203. View

Li C, Cheng P, Liang M, Chen Y, Lu Q, Wang J . MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest. 2015; 125(4):1509-22. PMC: 4396470. DOI: 10.1172/JCI77716. View

Wilson J, Keller S, Manganiello M, Cheng C, Lee C, Opara C . pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013; 7(5):3912-25. PMC: 4042837. DOI: 10.1021/nn305466z. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Cantrill J, Anderson D . Treatment of Paget's disease of bone. Clin Endocrinol (Oxf). 1990; 32(4):507-18. DOI: 10.1111/j.1365-2265.1990.tb00892.x. View

10.

Neale J, Richter N, Merten K, Taylor K, Singh S, Waite L . Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett. 2009; 19(3):680-3. DOI: 10.1016/j.bmcl.2008.12.051. View

11.

Thamake S, Raut S, Gryczynski Z, Ranjan A, Vishwanatha J . Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 2012; 33(29):7164-73. DOI: 10.1016/j.biomaterials.2012.06.026. View

12.

Nguyen M, Carlini A, Chien M, Sonnenberg S, Luo C, Braden R . Enzyme-Responsive Nanoparticles for Targeted Accumulation and Prolonged Retention in Heart Tissue after Myocardial Infarction. Adv Mater. 2015; 27(37):5547-52. PMC: 4699559. DOI: 10.1002/adma.201502003. View

13.

Itaka K, Ohba S, Miyata K, Kawaguchi H, Nakamura K, Takato T . Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles. Mol Ther. 2007; 15(9):1655-62. DOI: 10.1038/sj.mt.6300218. View

14.

Gold L . The SELEX process: a surprising source of therapeutic and diagnostic compounds. Harvey Lect. 1995; 91:47-57. View

15.

Del Pozo-Rodriguez A, Delgado D, Solinis M, Gascon A . Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides. Recent Pat Drug Deliv Formul. 2011; 5(3):214-26. DOI: 10.2174/187221111797200515. View

16.

Yarbrough D, Hagerman E, Eckert R, He J, Choi H, Cao N . Specific binding and mineralization of calcified surfaces by small peptides. Calcif Tissue Int. 2009; 86(1):58-66. PMC: 2798077. DOI: 10.1007/s00223-009-9312-0. View

17.

Zhang G, Guo B, Wu H, Tang T, Zhang B, Zheng L . A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012; 18(2):307-14. DOI: 10.1038/nm.2617. View

18.

Widler L, Jahnke W, Green J . The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics. Anticancer Agents Med Chem. 2011; 12(2):95-101. DOI: 10.2174/187152012799014959. View

19.

Zhang Y, Wei L, Miron R, Shi B, Bian Z . Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res. 2014; 30(2):286-96. DOI: 10.1002/jbmr.2322. View

20.

Gu W, Wu C, Chen J, Xiao Y . Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomedicine. 2013; 8:2305-17. PMC: 3699134. DOI: 10.2147/IJN.S44393. View